domvanalimab + quemliclustat + zimberelimab

This drug is an experimental **combination immunotherapy** consisting of three investigational monoclonal antibodies: **domvanalimab** (an Fc-silent anti-TIGIT monoclonal antibody), **quemliclustat** (a small molecule inhibitor of CD73), and **zimberelimab** (an anti-PD-1 monoclonal antibody). - **Mechanism of Action**: - **Domvanalimab** targets TIGIT on immune cells, blocking an immune checkpoint that inhibits T-cell activation. - **Zimberelimab** inhibits PD-1, a key immune checkpoint receptor on T cells, thus enhancing anti-tumor immune activity. - **Quemliclustat** inhibits CD73, reducing adenosine production in the tumor microenvironment, which otherwise suppresses immune responses against cancer cells. The combination is being studied primarily in advanced solid tumors such as upper gastrointestinal cancers and non-small cell lung cancer to determine synergistic efficacy and safety, with chemotherapy often added to the regimen.

Other names

domvanalimab + quemliclustat + zimberelimab